WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has partnered with New Growth Advisors (NGA), a prominent life sciences consulting firm, to explore strategic options for its cardiovascular portfolio. The collaboration will focus on potential out-licensing transactions or asset sales, aiming to maximize the value of Windtree’s innovative cardiovascular assets.
Windtree plans to leverage the positive outcomes from its clinical programs, including results from its recent Phase 2b SEISMiC trial in early cardiogenic shock, a condition marked by low blood pressure following a heart attack. The company sees these results as a pivotal step in advancing istaroxime, its novel dual-mechanism therapy targeting SERCA2a activation. The engagement with NGA will also extend to Windtree’s next-generation, oral SERCA2a activators, with efforts aimed at securing partnerships or licensing deals for global territories outside of Greater China.
Windtree already has an existing agreement with Lee’s Pharmaceuticals (HK) Limited for the Greater China region. This partnership could provide up to $138 million in milestone payments and low double-digit royalties while Lee’s shoulders all development costs. Lee’s is also planning to launch Phase 3 trials for acute heart failure in its licensed region by mid-2025.
“There is heightened interest in innovative cardiovascular assets among major pharmaceutical companies,” said Jed Latkin, CEO of Windtree Therapeutics. “With four positive Phase 2 studies, including our achievements in early cardiogenic shock, we believe now is the right time to pursue a broader outreach guided by an experienced advisor. A partnership could propel our cardiovascular program forward, while proceeds may also support the development of our preclinical oncology platform.”
By collaborating with NGA, whose advisory experience spans transactions nearing $400 million in value, Windtree aims to capitalize on growing market interest in groundbreaking cardiovascular treatments. The company’s strategic efforts underscore its commitment to advancing life-saving therapies while preparing for future opportunities in oncology.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.